Median Cost of Cancer Drug Development $648.0 Million
Total revenue from sales of 10 drugs was $67.0 billion, with total R&D spending of $7.2 billion
Zika Virus Preferentially Targets Glioblastoma Stem Cells
ZIKV preferentially infects, kills GSCs relative to differentiated tumor progeny, normal neuronal cells
Diverse Neurological Effects Linked to Anti-PD-1 Therapy
Complications seen after median of 5.5 cycles of anti-PD-1-inhibitors; include myopathy, neuropathies
Vaccine-Type HPV Rates Down for Unvaccinated Young Women
Significant decrease among unvaccinated women aged 18 to 26 years from 2009-2010 to 2013-2014
Strong Evidence for Healthy Lifestyle Reducing CRC Risk
Consuming whole grains, foods with dietary fiber, dairy products reduces risk of colorectal cancer
No Difference in Toxicity for 6-, 2-Fraction HDR in Prostate Cancer
Urinary, sexual toxicity similar with 6-, 2-fraction high-dose-rate brachytherapy regimen
Immune Status Tied to Outcomes in Third-Gen CAR T-Cell Therapy
In leukemia/lymphoma, after treatment CD19-targeting chimeric antigen receptor T-cell therapy
Inactivated Vaccinia Virus Shows Promise Against Advanced Cancer
Combined with immune checkpoint blockade therapy, iMVA generates synergistic antitumor effects
Mailed Invitations Increase CRC Screening Completion
And providing specific reminders to general practitioners improves participation in FIT screening
Universal Sequencing of Cancer Genes Ups Mutation Detection
Increased detection of heritable mutations over the predicted yield of testing based on guidelines
